KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy.

ABSTRACT:

Background and purpose

KRAS and BRAF are mutated in 35% and 10% of colorectal cancers, respectively. However, data specifically for locally advanced rectal cancers are scarce, and the frequency of KRAS mutations in codons 61 and 146 remains to be established.

Materials and methods

DNA was isolated from pre-therapeutic biopsies of 94 patients who were treated within two phase-III clinical trials receiving preoperative chemoradiotherapy. Mutation status of KRAS exons 1-3 and BRAF exon 15 was established using the ABI PRISM Big Dye Sequencing Kit and subsequently correlated with clinical parameters.

Results

Overall, KRAS was mutated in 45 patients (48%). Twenty-nine mutations (64%) were located in codon 12, 10 mutations (22%) in codon 13, and 3 mutations (7%) in codons 6

SUBMITTER: Gaedcke J 

PROVIDER: S-EPMC7373270 | biostudies-literature | 2010 Jan

REPOSITORIES: biostudies-literature